GATA binding protein 5Genealiases: CHTD5 · GATAS · bB379O24.1
Q-omics provides the consensus-scored GATA5 profile across patient tissues and cancer cell-line models. GATA5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GATA5 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GATA5 protein abundance shows 17,756 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where GATA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATA5 survival associations across molecular data types. GATA5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATA5 RNA expression–survival associations across cancer types. High GATA5 expression shows unfavorable associations in ACC, UVM, LUSC and THYM, but favorable associations in KIRC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GATA5 RNA expression.
This table summarizes GATA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GATA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATA5 shows lower tumor expression in KIRC, BLCA, KICH, KIRP and LUAD and higher tumor expression in BRCA. The KIRC box plot shows higher GATA5 RNA expression in normal versus tumor tissue (log2 FC = −1.816, t-test p < 0.001).
This table shows molecular features associated with GATA5 in patient tissues and cancer cell lines. In patient samples, GATA5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GATA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
